Kunming biopharmaceutical technology innovation Leading cloud medicine "accelerated"

April 1, 2016

Source: xinhua

Xinhuanet Beijing on April 1 (YanShan), the world's first developed for the treatment of malaria artemisinin-based drugs; The world for the first time synthesis of gastrodine; Domestic first extracted from Laura fu wood fu wood alkaloids with antihypertensive effect is... In recent years, kunming group by using modern biological pharmaceutical technology, the latest research and development of innovation, realize the transformation and upgrading of cloud medicine "acceleration".

Use of biological pharmaceutical technology Secondary development cloud

Is the biological resources in yunnan province, 5050 kinds of natural medicine resources, account for more than 50% of the national natural medicine. In recent years, with the rapid upgrading of biopharmaceutical technology worldwide, biological medicine industry has become the most potential industry in yunnan. In 2014, biological medicine industry of yunnan economy has amounted to 101.3 billion yuan, which realize the plant output value 21.8 billion yuan, gross industrial output value of 34.8 billion yuan, business sales income is 44.7 billion yuan.

As early as 1966, kunming group has used the biological transformation and drug synthesis, isolated from lijiang mountain arrowhead of antitumor and anti gout colchicine (Colchine), and half the drug synthesis research, developed the "injection" autumn crack amine, fill the blank of domestic relevant medical market, created the biopharmaceutical precedent; In 1970, kunming group cooperation with Beijing pharmaceutical industry research institute, developed from yunnan to produce cinchona bark quinine sulfate, isolated and its optical isomer, quinidine sulfate; In 1973, kunming group in cooperation with yunnan institute of drug and so on, from xishuangbanna botanical extract isolated tin tin raw rattan plants raw rattan alkaloid, developed as dai muscle relaxant injection; In 1979, kunming group cooperation with plants in kunming, the development of synthetic gastrodine, so far as one of the world's largest synthetic nucleoside drugs; In 1985, extracted from bean curd fruit decay shenshuaiguo god, god made failure shenshuaiguo tablet; In 2006, from its lamps flowers b element extracted lamps...

Biopharmaceutical technology in order to better development, in recent years, kunming group drugs pharmaceutical science park was established in yunnan kunming, create "intelligent key process and key positions robots substitute, intelligent optimization control of the production process, the supply chain optimization" intelligent digital manufacturing base, is committed to creating the world's leading, the domestic first-class scale, specialization, internationalization biomedical park.

At present, the kunming group pay more attention to the use of biological pharmaceutical technology secondary development and old product. Such as in the secondary development of compound artemether, found that it not only has worked well in the treatment of malaria, are also has a good curative effect; And in depth development of gastrodia elata, identify areas in the treatment of disease of heart head blood-vessel has its special effect, and thus developed the second generation product b gastrodine and its tablets.

Layout of the overseas new biological pharmaceutical system To speed up the cloud medicine "go out"

Drug firms cannot leave a high level r&d talents, kunming group has been the talents as the key point of the development of the enterprise. Currently has stroke treatment biology science and technology innovation team, Diabegone project team, biology, drug research and evaluation of innovation team structure innovation team, new medicine r&d innovation team "big five" biological pharmaceutical talents team, innovation and set up a post-doctoral scientific research workstation. After continuous efforts, kunming group currently has 235 drug patents, licensing 168 items, including 183 invention patents, drug authorized 65 items.

In recent years, with the rapid development of the enterprise, kunming accelerated the pace of entering international group. The investment in the United States in 2015 Rani Therapeutics of "sugar needle capsule" project, in March this year the company announcement again, in the United States will work with the pharmaceutical association to set up the "north American drug development center of kunming group", a series of based on the treatment of chronic disease treatment in the field of new drug research. At the same time, the company will also invest in CPI (Coordination Pharmaceuticals, INC.) co., LTD., $2.5 million, a series of based on nanometer technology in the treatment of gastric cancer, colon cancer and other anti-tumor drugs research and development.

When it comes to the development of the future, kunming group, says the company will set up in Shanghai, with emphasis on the biological pharmaceutical research and development base; In yunnan, with emphasis on the plant medicine r&d and manufacturing base; In Beijing, with emphasis on the chemical medicine research and development base. At the same time, in Japan, the United States, European countries actively seeking advantage cooperation projects, to kunming baker NORTON co., LTD., for the international market of medicine preparations production sales platform, to the United States Rani Therapeutics of "sugar needle capsule" project as a starting point, layout of the overseas new biomedical system, speed up the cloud of "going out".